Skip to main content
    V

    Virax Biolabs Group Limited Ordinary Shares (VRAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.45
    -0.16 (-26.87%)

    Market Cap: $823,940

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Virax Biolabs Group Limited Ordinary Shares (VRAX) Financials: Revenue, Profit and Cash Flow

    Updated Jul 1, 2026. Financial statements from company filings, amounts in US dollars.

    Virax Biolabs Group Limited Ordinary Shares reported revenue of $12.42K for the fiscal year ended Mar 31, 2026, up 96.2% from the year before. That year, net income was -$5.02M with a net margin of -40439.1%, operating cash flow was -$4.62M and free cash flow was -$4.88M. The quarter ended Jun 30, 2026 had revenue of $12.42K and net income of -$5.02M.

    Revenue and Margins

    Over the 6 years to Mar 2026, revenue fell from $99.88K, a compound annual decline of 29.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$12.42K+96.2%61.9%-51515.2%-40439.1%
    Mar 2025$6.33K-96.0%-838.2%-97344.8%-95739.2%
    Mar 2024$156.42K+1727.1%32.3%-4153.3%-4304.8%
    Mar 2023$8.56KN/A-15.9%-66963.7%-63748.3%
    Mar 2022$0-100.0%N/AN/AN/A
    Mar 2021$123.82K+24.0%-7.6%-520.5%-525.8%
    Mar 2020$99.88KN/A45.8%-652.1%-802.1%
    Annual, fiscal years ended Mar 2020 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    Revenue$12.42K$6.33K$156.42K$8.56K$0$123.82K$99.88K
    Cost of revenue$4.73K$59.40K$105.83K$9.93K$0$133.25K$54.13K
    Gross profit$7.69K-$53.07K$50.59K-$1.36K$0-$9.43K$45.75K
    Research and development$3.74M$1.78M$1.56M$397.11K$433.74K$120.22K$87.00K
    Operating income-$6.40M-$6.16M-$6.50M-$5.73M-$1.73M-$644.54K-$651.24K
    Net income-$5.02M-$6.06M-$6.73M-$5.46M-$1.71M-$650.98K-$801.13K
    EBITDA-$5.43M-$5.80MN/A-$5.44M-$750$266$2.47K
    Fiscal years ended Mar 2020 to Mar 2026

    Quarterly

    Line itemJun 2026Sep 2025Jun 2025Sep 2024Jun 2024Sep 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021
    Revenue$12.42K$1.61K$1.38K$4.95K$79.92K$76.50K$2.80K$2.80K$5.76K-$92.86K-$92.86K$30.95K
    Gross profit$7.69K-$215.41K-$46.59K-$6.47K$40.07K$10.52K-$1.48K-$1.48K$118-$192.81KN/AN/A
    Operating income-$6.40M-$2.59M-$3.28M-$2.88M-$3.79M-$2.71M-$4.29M-$4.29M-$1.44M-$1.17MN/AN/A
    Net income-$5.02M-$2.34M-$3.30M-$2.76M-$3.82M-$2.91M-$4.01M-$4.01M-$1.44M-$1.16M-$427.39KN/A
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded short-term debt of $109.58K by $6.33M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    Total assets$8.32M$6.43M$5.48M$9.81M$48.71K$94.12K$22.61K
    Current assets$6.83M$4.89M$4.38M$9.63M$48.71K$39.62K$22.61K
    Cash and equivalents$6.44M$4.23M$3.59M$9.35M$21.76K$17.62K$22.61K
    Total liabilities$989.83K$964.75K$345.19K$908.40K$1.25M$871.43K$1.24M
    Short-term debt$109.58K$85.46K$47.95K$146.25K$3.76K$179.48K$759.37K
    Shareholder equity$7.58M$5.70M$5.37M$9.13M-$974.58K-$596.18K-$1.06M
    Fiscal years ended Mar 2020 to Mar 2026

    Quarterly

    Line itemJun 2026Mar 2026Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Sep 2023Mar 2023Dec 2022Sep 2022
    Total assets$8.32M$8.32M$5.72M$6.43M$6.43M$9.44M$5.48M$5.48M$7.03M$9.81M$9.81M$5.30M
    Total liabilities$989.83K$989.83K$641.52K$964.75K$964.75K$1.03M$345.19K$345.19K$919.05K$908.40K$908.40K$1.14M
    Cash and equivalents$6.44M$6.44M$3.35M$4.23M$4.23M$7.29M$3.59M$3.59M$5.11M$9.35M$9.35M$4.57M
    Shareholder equity$7.58M$7.58M$5.31M$5.70M$5.70M$8.64M$5.37M$5.37M$6.33M$9.13M$9.13M$4.39M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    Operating cash flow-$4.62M-$4.56M-$6.25M-$4.18M-$809.07K-$590.19K-$744.61K
    Capital expenditures$255.83K$603.89K$1.16M$178.40K$0$0$0
    Free cash flow-$4.88M-$5.17M-$7.41M-$4.36M-$809.07K-$590.19K-$744.61K
    Investing cash flow-$255.83K-$603.89K-$1.16M-$178.40K-$178.40K-$178.40K-$178.40K
    Financing cash flow$7.09M$5.81M$1.65M$13.69M$813.21K$585.20K$704.64K
    Fiscal years ended Mar 2020 to Mar 2026

    Quarterly

    Line itemJun 2026Sep 2025Jun 2025Sep 2024Jun 2024Sep 2023Mar 2023Dec 2022
    Operating cash flow-$4.62M-$2.92M-$2.45M-$1.92M-$2.79M-$3.46M-$1.88M-$1.88M
    Capital expenditures$255.83K$141.50K$355.89K$248.00K$459.92K$708.18K$178.40K$178.40K
    Free cash flow-$4.88M-$3.06M-$2.81M-$2.17M-$3.25M-$4.17M-$2.06M-$2.06M
    Last 8 quarters

    Frequently Asked Questions About VRAX

    What is Virax Biolabs Group Limited Ordinary Shares' annual revenue?

    Virax Biolabs Group Limited Ordinary Shares reported revenue of $12.42K for the fiscal year ended Mar 31, 2026.

    How fast is Virax Biolabs Group Limited Ordinary Shares' revenue growing?

    Revenue was up 96.2% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 13.2%.

    Is Virax Biolabs Group Limited Ordinary Shares profitable?

    No. Virax Biolabs Group Limited Ordinary Shares reported net income of -$5.02M for the fiscal year ended Mar 31, 2026, with a net margin of -40439.1%.

    How much free cash flow does VRAX generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$4.62M minus capital expenditures of $255.83K produced free cash flow of -$4.88M.

    How much debt does Virax Biolabs Group Limited Ordinary Shares have?

    The balance sheet dated Mar 31, 2026 reported short-term debt of $109.58K and cash and equivalents of $6.44M.